新藥物遞輸系統(NDDS)的全球市場:各給藥途徑、NDDS的方式、地區 - 成長，趨勢，及預測(2018年∼2023年)
Novel Drug Delivery Systems (NDDS) Market - Segmented by Route of Administration, Mode of NDDS, Geography - Growth, Trends, and Forecast (2018 - 2023)
|出版商||Mordor Intelligence LLP||商品編碼||390732|
|出版日期||內容資訊||英文 141 Pages
|新藥物遞輸系統(NDDS)的全球市場:各給藥途徑、NDDS的方式、地區 - 成長，趨勢，及預測(2018年∼2023年) Novel Drug Delivery Systems (NDDS) Market - Segmented by Route of Administration, Mode of NDDS, Geography - Growth, Trends, and Forecast (2018 - 2023)|
|出版日期: 2019年01月01日||內容資訊: 英文 141 Pages||
The novel drug delivery systems market is expected to witness a CAGR of 2.9%, during the forecast period, 2018-2023. There is a continuous growth in the market of drug delivery systems and is forecasted to continue to grow at an impressive rate in future also.
Requirement of Controlled Release of Drugs
The method by which a drug is being delivered can have significant influence on its efficacy. Many of the drugs have an optimum concentration range and requirement of controlled release of drugs in the body has to be there. The concentrations above or below the concentration range can be toxic or can produce no therapeutic benefits at all. Transdermal patches, implants, nasal systems, microcapsules, etc. are some of the common systems that are considered under the controlled release systems. Hence, the requirement of controlled release of drugs leads to drive the novel drug delivery systems market.
The other factors include advancement in pharmacology promoting increased adoption of novel drug delivery systems (NDDS) and technological advancements promoting development of NDDS.
Stability Issues with the NDDS System
The stability of the delivery system is one of the most important factors, which effects the drug delivery systems market. Liposomes are the most common nanocarriers for drug delivery owing to the several advantages they offer over other delivery systems. Liposomes help in stabilizing therapeutic compounds and improved biodistribution of compounds to target sites in vivo. However, stability of liposome-based drug delivery systems is a major concern, which is restraining the growth of this market.
The other restraining factors also include the stringent regulatory guidelines and product recalls.
North America Dominates the Market
North America has dominated the novel drug delivery systems in cancer therapy market in 2016 with a revenue share of around 37%. North America holds the major share in the market owing to the factors, such as growing R&D in the field of drug delivery systems, the high adoption rate of new technologies, and supportive reimbursement policies. Asia Pacific is also expected to witness growth in the novel drug delivery systems market in the upcoming future.
Key Developments in the Market
The major players include - Abbott Laboratories, AstraZeneca PLC, Bayer Healthcare Pharmaceuticals, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Novartis AG, Pfizer Inc., Roche Holding AG and Sanofi SA, among others.
Reasons to Purchase this Report:
Customization of the Report:
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
7. Market Segmentation
8. Competitive Landscape
9. Key Players
*List Not Exhaustive
10. Future of The Market